When human FcRn transgenic tumor-bearing mice were treated with either an anti-EGFR antibody or an anti-VEGF antibody containing the M428L/N434S mutations, an increased reduction in tumor burden was observed compared with IgG1 treated animals (Zalevsky et al., 2010). The gene discussed is FCGRT; the disease is neoplasm.